Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.6957
-0.05-7.24%
At close: -
$0.6749
-0.02-2.99%
After Hours: 7:40 PM EDT
Comments
Loading...
Milestone Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:MIST | Benzinga
Milestone Pharmaceuticals Inc has a consensus price target of $8.33 based on the ratings of 6 analysts. The high is $13 issued by Oppenheimer on April 12, 2023. The low is $4 issued by Jefferies on June 20, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on April 1, 2025, March 28, 2025, and March 17, 2025, respectively. With an average price target of $20 between HC Wainwright & Co., there's an implied 2863.40% upside for Milestone Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Rodman & Renshaw
Piper Sandler
TD Cowen
Jefferies
1calculated from analyst ratings
Analyst Ratings for Milestone Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/01/2025 | Buy Now | 1381.7% | HC Wainwright & Co. | Patrick Trucchio37% | $25 → $10 | Maintains | Buy | Get Alert |
| 03/28/2025 | Buy Now | 3604.25% | HC Wainwright & Co. | Patrick Trucchio37% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 03/17/2025 | Buy Now | 3604.25% | HC Wainwright & Co. | Patrick Trucchio37% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2025 | Buy Now | 3604.25% | HC Wainwright & Co. | Patrick Trucchio37% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 01/27/2025 | Buy Now | 3604.25% | HC Wainwright & Co. | Patrick Trucchio37% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 10/14/2024 | Buy Now | 3604.25% | HC Wainwright & Co. | Patrick Trucchio37% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2024 | Buy Now | 3604.25% | HC Wainwright & Co. | Patrick Trucchio37% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2024 | Buy Now | 1233.53% | Rodman & Renshaw | Brandon Folkes40% | → $9 | Initiates | → Buy | Get Alert |
| 07/01/2024 | Buy Now | 3604.25% | HC Wainwright & Co. | Patrick Trucchio37% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2024 | Buy Now | 3604.25% | HC Wainwright & Co. | Patrick Trucchio37% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2024 | Buy Now | 3604.25% | HC Wainwright & Co. | Patrick Trucchio37% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 03/22/2024 | Buy Now | 3604.25% | HC Wainwright & Co. | Patrick Trucchio37% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2024 | Buy Now | 640.85% | Piper Sandler | Edward Tenthoff51% | $6 → $5 | Maintains | Overweight | Get Alert |
| 02/26/2024 | Buy Now | 3604.25% | HC Wainwright & Co. | Patrick Trucchio37% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 12/27/2023 | Buy Now | 1233.53% | TD Cowen | — | $17 → $9 | Maintains | Outperform | Get Alert |
| 08/14/2023 | Buy Now | 3604.25% | HC Wainwright & Co. | Patrick Trucchio37% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2023 | Buy Now | 492.68% | Jefferies | Chris Howerton63% | $8 → $4 | Downgrade | Buy → Hold | Get Alert |
| 05/23/2023 | Buy Now | 3604.25% | HC Wainwright & Co. | Patrick Trucchio37% | → $25 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | 3604.25% | HC Wainwright & Co. | Patrick Trucchio37% | → $25 | Reiterates | Buy → Buy | Get Alert |
| 04/12/2023 | Buy Now | 1826.21% | Oppenheimer | Leland Gershell67% | $16 → $13 | Maintains | Outperform | Get Alert |
| 03/30/2023 | Buy Now | 3604.25% | HC Wainwright & Co. | Patrick Trucchio37% | → $25 | Reiterates | → Buy | Get Alert |
| 03/09/2023 | Buy Now | 3604.25% | HC Wainwright & Co. | Patrick Trucchio37% | → $25 | Reiterates | → Buy | Get Alert |
| 11/14/2022 | Buy Now | 3604.25% | HC Wainwright & Co. | Patrick Trucchio37% | $20 → $25 | Maintains | Buy | Get Alert |
| 04/22/2022 | Buy Now | 1381.7% | Piper Sandler | Edward Tenthoff51% | $8 → $10 | Upgrade | Neutral → Overweight | Get Alert |
FAQ
What is the target price for Milestone Pharmaceuticals (MIST) stock?
The latest price target for Milestone Pharmaceuticals (NASDAQ:MIST) was reported by HC Wainwright & Co. on April 1, 2025. The analyst firm set a price target for $10.00 expecting MIST to rise to within 12 months (a possible 1381.70% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Milestone Pharmaceuticals (MIST)?
The latest analyst rating for Milestone Pharmaceuticals (NASDAQ:MIST) was provided by HC Wainwright & Co., and Milestone Pharmaceuticals maintained their buy rating.
When was the last upgrade for Milestone Pharmaceuticals (MIST)?
The last upgrade for Milestone Pharmaceuticals Inc happened on April 22, 2022 when Piper Sandler raised their price target to $10. Piper Sandler previously had a neutral for Milestone Pharmaceuticals Inc.
When was the last downgrade for Milestone Pharmaceuticals (MIST)?
The last downgrade for Milestone Pharmaceuticals Inc happened on June 20, 2023 when Jefferies changed their price target from $8 to $4 for Milestone Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Milestone Pharmaceuticals (MIST)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Milestone Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Milestone Pharmaceuticals was filed on April 1, 2025 so you should expect the next rating to be made available sometime around April 1, 2026.
Is the Analyst Rating Milestone Pharmaceuticals (MIST) correct?
While ratings are subjective and will change, the latest Milestone Pharmaceuticals (MIST) rating was a maintained with a price target of $25.00 to $10.00. The current price Milestone Pharmaceuticals (MIST) is trading at is $0.67, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.